<DOC>
	<DOCNO>NCT00156780</DOCNO>
	<brief_summary>This study conduct evaluate safety pharmacokinetics echocardiographic contrast agent , AI-700 , patient moderate severe chronic obstructive pulmonary disease ( COPD ) and/or congestive heart failure ( CHF ) .</brief_summary>
	<brief_title>Phase 1 Safety Pharmacokinetic Study AI-700 Patients With Diminished DLCO COPD and/or CHF</brief_title>
	<detailed_description>In ongoing clinical trial , AI-700 currently evaluate value provide enhance echocardiography detect CAD . The patient population comprise patient chest pain evaluate inducible ischemia . This population may include patient compromised pulmonary function due COPD CHF . This study evaluate safety AI-700 patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>None</criteria>
	<gender />
	<minimum_age />
	<maximum_age />
	<verification_date>July 2006</verification_date>
	<keyword>ultrasound contrast agent</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>safety</keyword>
</DOC>